Celligenics

What Celligenics does

Celligenics Pte. Ltd. is a Singapore-based regenerative biotechnology company, founded in 2016 as a spin-off from A*STAR (the Agency for Science, Technology and Research), developing proprietary stem cell secretome technology for real-world regenerative applications. The company's core platform is built on the regenerative substances released by stem cells, including growth factors, cytokines, peptides, and extracellular vesicles, collectively referred to as the secretome. Celligenics' differentiating technical claims rest on three pillars: source-led purity (selected stem cell sources, notably human Wharton's jelly mesenchymal stem cells, combined with proprietary source-to-secretome know-how), cell-free regeneration (avoiding the safety, ethical, and regulatory complexity of live-cell therapies), and a complete secretome profile (broader than exosome-only approaches). The platform has been validated through institutional collaborations with NTU Singapore and the Skin Research Institute of Singapore (SRIS) under the Skin Innovation Grant, and through peer-reviewed publication of wound healing assay research in Springer Nature's Histochemistry and Cell Biology in 2024.

Celligenics monetises its platform across four application verticals: Therapeutics (tissue repair, functional recovery, degenerative conditions such as chronic wounds including diabetic foot ulcers and bed sores), Cosmeceuticals (advanced skin renewal, post-procedure recovery, aesthetic care), Veterinary (wound recovery, mobility support, tissue repair for companion and performance animals), and Longevity (healthy ageing, recovery, resilience). The company is pre-commercial and pre-revenue, with anticipated revenue streams structured around licensing/royalties for therapeutics and one-time license or OEM supply arrangements for cosmeceuticals, veterinary, and longevity products. Go-to-market is enterprise-led, pursuing B2B partnerships, research collaborations with universities and clinical institutes, and OEM arrangements with commercial partners. The lead commercial vehicle is a strategic MOU signed in April 2021 with Series A investor Best World International (BWI) for the development and launch of next-generation stem cell-based healthcare and wellness products. The company is headquartered in Singapore's Biopolis biomedical hub (Matrix @ Biopolis, 30 Biopolis Street) and, as of March 2023, has selected Chengdu, China, as its China headquarters, signing an MOU with West China Hospital of Sichuan University and announcing plans for an Advanced Therapeutics Development Centre in Chengdu's High-Tech Industrial Development Zone.

The company has raised S$5.6 million in Series A funding (January 2019) from BWI, which holds at least a 12.5% stake at a S$44.8 million post-money valuation. Leadership includes Founder and CEO Kurt Wee, Board Chairman Yeoh Oon Jin (former Chairman of PwC Singapore), COO Dr. Pauline Tay (ex-National Research Foundation), Scientific Director Dr. Pamela Mok, and Scientific Advisors Prof. David Becker (NTU Lee Kong Chian School of Medicine) and Prof. Amittha Wickrema (University of Chicago, cGMP Cell Therapy Facility). Celligenics has been recognised among A*STAR's top biotech start-ups (2018) and as a Top 15 finalist for Singapore's Emerging Enterprise Award (2021).

Name

Celligenics

Legal name

Celligenics Pte. Ltd.

Website

https://celligenics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Celligenics is a Singapore-based regenerative biotechnology company, spun out of A*STAR in 2016, that develops a proprietary cell-free stem cell secretome platform for tissue repair, chronic wound healing, and aesthetic applications across therapeutics, cosmeceuticals, veterinary, and longevity verticals.

Ownership category

akta.pro rank

Product category

Regenerative Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Stem cell therapeutics
• Regenerative biologics
• Secretome technology
• Tissue repair solutions
• Cell-free regeneration

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutics: Development of secretome-based therapeutic products for tissue repair, functional recovery, and degenerative conditions targeting unmet clinical needs. Revenue anticipated from licensing, co-development deals, or commercial launch upon regulatory approval.
2. Cosmeceuticals: Formulated products for advanced skin renewal, post-procedure recovery, and aesthetic care, from professional clinic use to daily care. Revenue expected through product sales, OEM supply, or licensing to commercial partners.
3. Veterinary Products: Applied to animal health needs including wound recovery, mobility support, and tissue repair, with potential across companion and performance animals.
4. Longevity / Wellness: Centred on wellness-oriented solutions for healthy ageing, recovery, resilience, and long-term biological function, targeting consumer and clinical wellness markets.
5. Strategic OEM / Co-development (Best World International): MOU with Series A investor Best World International for development and launch of next-generation stem cell-based healthcare and wellness products, potentially through OEM or co-development arrangements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Celligenics develops a proprietary stem cell secretome platform that captures regenerative substances (growth factors, cytokines, peptides, extracellular vesicles) released by stem cells, applying this technology across four application verticals: Therapeutics (tissue repair and degenerative conditions), Cosmeceuticals (skin renewal and aesthetic care), Veterinary (animal wound recovery and mobility), and Longevity (healthy ageing and wellness). The cell-free, complete secretome platform is positioned for licensing, OEM supply, and co-development with commercial and clinical partners.

Product overview

Celligenics operates as a regenerative biotech company built around its proprietary Secretome Platform. The platform harnesses stem cell-released regenerative substances including growth factors, cytokines, peptides, and extracellular vesicles. The company applies this technology across four application verticals: Therapeutics (tissue repair and degenerative conditions), Cosmeceuticals (skin renewal and aesthetic care), Veterinary (animal wound recovery and mobility support), and Longevity (wellness and healthy ageing solutions). The platform's key differentiators include source-led purity for consistent profiles, cell-free regeneration avoiding live-cell delivery complexity, and complete secretome composition beyond exosome-only approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutics (Secretome-based) Secretome-based therapeutic products in development for tissue repair, functional recovery, and degenerative conditions where regenerative biologics may support unmet clinical needs, including chronic wound healing (e.g., diabetic foot ulcers, bed sores). Revenue anticipated from licensing, co-development deals, or commercial launch upon regulatory approval.
• Cosmeceuticals Formulated secretome-based cosmeceutical products for advanced skin renewal, post-procedure recovery, and aesthetic care, ranging from professional clinic use to daily care, with revenue expected through product sales, OEM supply, or licensing to commercial partners.
• Veterinary Products Secretome-based products applied to animal health needs including wound recovery, mobility support, and tissue repair, with potential across companion and performance animals, intended for licensing to animal health partners.
• Longevity / Wellness Wellness-oriented secretome-based solutions for healthy ageing, recovery, resilience, and long-term biological function, targeting consumer and clinical wellness markets through licensing arrangements.
• In Vitro Delayed Scratch Closure Assay Research assay developed by Celligenics that mimics chronic wound features for therapeutic research, published in the Springer Nature journal Histochemistry and Cell Biology in May 2024, supporting chronic wound evaluation and secretome activity testing.

Quantifiable outcome

• Complete wound closure demonstrated in in vitro chronic wound model using Celligenics secretome derived from human Wharton's jelly MSCs

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• West China Hospital (Hua Xi) of Sichuan UniversitycoreStrategic or Co-development Partner · 1 March 2023MOU signed at the 22nd Singapore-Sichuan Trade and Investment Committee Meeting to mark Celligenics' entry into the China market. Celligenics also plans to develop an Advanced Therapeutics Development Centre in Chengdu's High-Tech Industrial Development Zone.
• Enterprise Singapore (ESG)minorOthers · 1 March 2023Enterprise Singapore (ESG) provided support for Celligenics' China market entry endeavour, facilitating the expansion of a Singapore biotech company into international markets.
• Nanyang Technological University, Singapore (NTU Singapore) — Lee Kong Chian School of MedicinecoreStrategic or Co-development Partner · 1 September 2021Research collaboration under the Skin Innovation Grant (SIG) to develop therapies that accelerate healing in chronic wounds such as diabetic foot ulcers and bed sores. Preliminary studies showed outstanding results.
• Skin Research Institute of Singapore (SRIS)coreStrategic or Co-development Partner · 1 September 2021Research collaboration with NTU Singapore and SRIS under the Skin Innovation Grant (SIG) to develop therapies for chronic wounds. SRIS is jointly established by A*STAR, National Skin Centre, and Nanyang Technological University.
• Changi General Hospital (CGH)minorStrategic or Co-development Partner · 1 March 2020Visit to CGH's Wound Care Clinic with SRIS to gain clinical insights into caring for patients with chronic wounds, sharing invaluable clinical perspectives for product development.
• A*STAR (Agency for Science, Technology and Research)coreStrategic or Co-development Partner · 1 February 2020Celligenics is an A*STAR spin-off founded in 2016. The company participates in A*STAR ecosystem initiatives including dialogue sessions and the Experimental Drug Development Centre, and was recognised among A*STAR's top biotech start-ups in 2018.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Mesoblast Limited: ASX-listed regenerative medicine company developing mesenchymal lineage cell-based therapeutics for inflammatory and degenerative conditions. Most directly comparable to Celligenics given its MSC-derived biologic approach; competes for the same scientific narrative and clinical indications in tissue repair.
• ExoCoBio: South Korean biotech developing exosome and MSC-conditioned-media-based regenerative products across therapeutics and cosmeceuticals. Closely comparable technology architecture (cell-free, MSC-derived regenerative biologics) and similar multi-vertical go-to-market across therapeutics, aesthetics, and animal health.
• Evox Therapeutics: UK-based exosome therapeutics company engineering extracellular vesicles to deliver regenerative and disease-modifying payloads. Overlaps with Celligenics on the extracellular-vesicle component of the secretome and on cell-free regenerative mechanism, with similar preclinical-to-clinical translation pathway.
• Capricor Therapeutics: Clinical-stage biotech developing cell-derived extracellular vesicle and cell therapy products for rare diseases and inflammation. Comparable through its use of cell-derived regenerative biologics and pursuit of degenerative-condition indications; differs in being clinical-stage and publicly listed.
• Direct Biologics: US regenerative medicine company developing MSC-derived exosome and biologic products for wound healing, orthopaedics, and inflammatory conditions. Direct overlap with Celligenics' MSC-source, exosome/secretome-based regenerative platform and wound-healing use case.
• Kimera Labs: US-based company developing and commercialising MSC-derived exosome products across clinical, cosmetic, and veterinary applications. Directly comparable multi-vertical monetisation (therapeutics, cosmeceuticals, veterinary) of an MSC-exosome platform.

Emerging players

• EVerZom: French biotech developing engineered extracellular vesicles/exosomes for regenerative medicine. Comparable cell-free extracellular-vesicle regenerative mechanism but earlier-stage and more focused on bioengineered vesicles rather than natural MSC secretome.

Broad incumbents

• Pluristem Therapeutics: Public regenerative medicine company developing placenta-derived cell therapy products for inflammatory and ischaemic conditions. Comparable in cell-based regenerative biology and degenerative-disease targeting, though it uses live-cell delivery rather than cell-free secretome.
• AgeX Therapeutics: US biotech focused on cell-based and regenerative medicine for ageing and age-related degenerative conditions. Overlaps with Celligenics on the longevity/wellness use case and the broader regenerative biology approach.

Regional players

• NextCell Pharma (Cellaviva): Swedish cell therapy company using Wharton's jelly-derived mesenchymal stem cells for inflammatory and autoimmune indications. Comparable MSC source (Wharton's jelly) and regenerative focus; serves European rather than APAC markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInsg.linkedin.com/company/celligenics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celligenics